TrialInternational journal of hematology2019

Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and A.R.R.O.W. Trials.

Meletios A Dimopoulos et al.PubMed ↗Publisher ↗

No numbers read from the abstract.